| Autor: |
Frerichs KA; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Nagy NA; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Lindenbergh PL; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Bosman P; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Marin Soto J; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Broekmans M; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Groen RWJ; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Themeli M; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Nieuwenhuis L; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Stege C; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Nijhof IS; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Mutis T; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Zweegman S; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., Lokhorst HM; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands., van de Donk NWCJ; a Department of Hematology , VU University Medical Center , Amsterdam , The Netherlands. |
| Abstrakt: |
Introduction: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is refractory to immunomodulatory drugs and proteasome inhibitors. Areas covered: This review will discuss the importance of CD38-targeting antibodies for the treatment of MM patients to improve their outcome. Expert commentary: Intense immuno-oncological laboratory research has resulted in the development of functionally active monoclonal antibodies against cell surface markers present on MM cells. In this respect, CD38-targeting antibodies such as daratumumab, MOR202, and isatuximab, have high single agent activity in heavily pretreated MM patients by virtue of their pleiotropic mechanisms of action including Fc-dependent effector mechanisms and immunomodulatory activities. Importantly, CD38-targeting antibodies are well tolerated, with infusion reactions as most frequent adverse event. Altogether, this makes them attractive combination partners with other anti-MM agents. Daratumumab is already approved as monotherapy and in combination with lenalidomide-dexamethasone as well as bortezomib-dexamethasone in pretreated MM patients. Furthermore, results from studies evaluating CD38-targeting antibodies in newly diagnosed MM patients are also promising, indicating that CD38-targeting antibodies will be broadly used in MM, resulting in further improvements in survival. |
